COMMENT ON HOME ET AL. Predictive and Explanatory Factors of Change in HbA1c in a 24-Week Observational Study of 66,726PeopleWith Type 2 Diabetes Starting Insulin Analogs.

We read with interest the results of the A1chieve study (1), a noninterventional, observational, 24-week study examining the safety and effectiveness of insulin analogs (detemir, aspart, biphasic aspart 30 [all Novo Nordisk, Bagsvaerd, Den-mark]) alone or in combination in rou-tine clinical use in 66,726 people with type 2 diabetes. The mean change in HbA1c level was 22.1 % (SD 1.7%) (–23 mmol/mol [19 mmol/mol]) in insulin-naive participants and 21.8 % (1.7%) (–19 mmol/mol [19 mmol/mol]) among insulin users. The factor explaining most of the variance in HbA1c change wa